How to Use Efpeglenatide
Complete guide to Efpeglenatide dosing, administration, timing, and protocol recommendations.
Quick Overview
Efpeglenatide is a long-acting, once-weekly GLP-1 agonist from Hanmi Pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. Sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. Hanmi relaunched it for obesity, and on 7 October 2026 South Korea approved it as Eppe, the country's first homegrown GLP-1 obesity drug. It is not approved by the FDA or EMA.
Dosing Guidelines
Common Dose
10 mg once weekly maintenance (Korean label)
Frequency
Once weekly
Dose Range
2-10 mg weekly, escalated over 12 weeks
Note: These doses come from the Korean approval and trials. Outside Korea it remains unapproved, and no other regulator has set a dose.
Administration Method
Subcutaneous auto-injector once weekly
Best Time to Take
Same day each week
The Fc-linked design gives it a long half-life, so weekly consistency matters more than time of day.
Protocol Duration
Long-term (chronic weight management); 40-64 weeks in the Korean phase 3
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Diarrhea (about 18% in the Korean phase 3)
- •Nausea (about 17%)
- •Indigestion
- •Constipation
- •Vomiting (about 12%)
Frequently Asked Questions
What is the recommended dose for Efpeglenatide?
10 mg once weekly maintenance (Korean label)
How do you administer Efpeglenatide?
Subcutaneous auto-injector once weekly
When is the best time to take Efpeglenatide?
Same day each week
How long should you use Efpeglenatide?
Long-term (chronic weight management); 40-64 weeks in the Korean phase 3
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.